Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.78
- Piotroski Score 5.00
- Grade Neutral
- Symbol (FLGT)
- Company Fulgent Genetics, Inc.
- Price $21.69
- Changes Percentage (2.5%)
- Change $0.53
- Day Low $21.16
- Day High $21.69
- Year High $30.68
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2. In addition, the company offers flow cytometry, a cell analysis technique providing diagnosis, prognosis, and monitoring of malignancies; fluorescence in-situ hybridization for detecting and locating a specific DNA sequence on a chromosome; immunohistochemistry, an imaging technique used to visualize antigens in cells; cytogenetics, which analyzes the chromosome set for numerical and structural abnormalities; and molecular testing that includes hematopoietic and solid tumor molecular assays. The company serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. Fulgent Genetics has strategic partnership with Helio Health, Inc. to commercialize blood-based early cancer detection tests. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 10/31/2024
- Fiscal Year End N/A
- Average Stock Price Target $45.00
- High Stock Price Target $50.00
- Low Stock Price Target $40.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.56
- Trailing P/E Ratio -3.65
- Forward P/E Ratio -3.65
- P/E Growth -3.65
- Net Income $-167,825,000
Income Statement
Quarterly
Annual
Latest News of FLGT
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Those who invested in Fulgent Genetics (NASDAQ:FLGT) five years ago are up 107%
Fulgent Genetics stock has seen a 107% rise in the last five years, with a 15% increase in the last quarter. Despite recent drops, long-term shareholders have gained 16% annually. Analyzing revenue gr...
By Yahoo! Finance | 1 week ago -
With 50% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing
Institutional ownership of over 50% in Fulgent Genetics gives them significant control over the company's decisions and stock price. CEO Ming Hsieh holds a 29% stake, with BlackRock and The Vanguard G...
By Yahoo! Finance | 3 months ago
